Lung Cancer at the Limits 2026
About the event
The inaugural Lung Cancer at the Limits (LCATL) conference is a two-day medical education meeting which brings together a notable faculty of globally acknowledged experts who will consider new discoveries and therapies at the limits of Lung Cancer treatments.
Accreditation
Accreditation wil be applied for.
Audience
Lung Cancer spacialists scientists & researchers.
Registration fee
Registration is free for HCPs and includes access to all scientific sessions.
Funders
Lung Cancer at the Limits is supported by way of grants or sponsorship from the pharmaceutical industry. Our supporters have no involvement in the organisation of this event, or the selection of speakers or topics which are handled entirely independently by the event Chairs. Supporters are invited to send a delegation of senior company representatives to attend, and their role is simply to continue building the crucial understanding between academia and industry in a scientific setting. Full disclosure of contacted supporters will appear on the event website and be available at the venue during the event.
Funders will host pharmaceutical industry promotional satellite symposia. The sessions are clearly marked on the agenda and will be introduced on-site.
Chairs
With a deep understanding of the challenges facing Lung Cancer specialists, the chairs bring a wealth of experience to the task of leading the event. In creating the meeting, they have drawn upon their personal awareness of the disease area, the ongoing knowledge shared by colleagues and the feedback from previous gatherings to ensure that the meeting is highly relevant and enjoyable for the expert community.
The Lancet
This meeting is endorsed and supported by the Lancet, The Lancet Oncology and eClinicalMedicine.
Contact us
If you require any assistance, please contact us
Follow us:
